2023-07-17 12:38:00
Ceva wants to play the game once more. The French group disputes the allocation by the State of the market for the manufacture of the future vaccine once morest avian flu to the German group Boehringer Ingelheim. The Frenchman says he is “particularly surprised by the decision of the French administration, which goes once morest the demands and concerns of breeders and sectors in many respects”. The company also says it regrets that the Ministry of Agriculture did not choose to distribute the order among the various respondents to the call for tenders. She therefore filed an interim order with the Paris administrative court to challenge this decision, she announced on July 17.
France had chosen last week the German company Boehringer Ingelheim for the supply of 80 million doses of vaccines once morest avian influenza. Two other groups were candidates: Ceva and the American Zoetis. The ministry specified that Boehringer Ingelheim’s offer was better than Ceva’s “with regard to the financial criteria, its ability to supply the doses and the storage conditions”.
VOS INDICES
source
With Archyde.com (Kate Entringer; editing by Zhifan Liu)
1689625083
#Ceva #challenges #choice #German #company #avian #flu #vaccine
